The company’s strategy comprises the development of novel, differentiated drugs for disorders in the central nervous system, a therapeutic segment with large remaining unmet medical needs. A key strategic priority is to efficiently advance drug candidates with well‑defined mechanisms of action through clinical development, followed by commercialization together with partners or by the company.
Umecrine Cognition develops product candidates for indications where there is a clear product-fit to fill therapeutic gaps, or in indications where there are few or no approved pharmacological treatments. By focusing on areas with well-defined and outspoken unmet needs, the company strives to develop products with the potential to transform current medical practice, by appearing attractive to all stakeholders – patients, doctors, regulatory agencies and reimbursing institutions.
Umecrine Cognition’s most advanced clinical drug candidate, golexanolone, exhibits a unique product profile that addresses important clinical needs, and is the only drug of its class in clinical development for neurological symptoms in Primary Biliary Cholangitis (PBC) such as fatigue and cognitive dysfunction.
Umecrine Cognition develops drugs under its own auspices and also intends to seek commercial collaborations with pharmaceutical companies to advance clinical development, or partners that can provide global distribution, marketing and commercial resources.